| HOME >> BIOLOGY >> TECHNOLOGY |
BALTIMORE, May 29 /PRNewswire/ -- FASgen Diagnostics, LLC (Baltimore) and Tetracore, Inc. (Rockville) have announced that they have entered into a collaboration to produce cGMP ELISA and IHC tests for cancer biomarkers using FASgen's proprietary antibodies. The tests measure the over-expression of the enzyme fatty acid synthase (FAS), which is found in virtually all solid tumor cancers. FASgen's FAS-detect(TM) Elisa and FAS-detect(TM) IHC tests, currently available for research purposes, have demonstrated repeated and highly significant success in identifying the progression of the disease in a series of different solid tumors, including, pancreas, ovarian, prostate and lung cancer. These research results were recently the subject of multiple independent papers and presentations at the AACR annual meeting and at the earlier annual meeting of the Society of Gynecological Oncologists.
FASgen Diagnostics and Tetracore have been working together for the
last six years and the current transaction expands the antibody and kit
production role to Tetracore's FDA approved GMP production facility.
Tetracore has previously been the primary source of certain new proprietary
FASgen antibodies that form the core of the FAS-detect(TM) Elisa and
FAS-detect(TM) IHC tests. Tetracore has also been given the opportunity to
invest in FASgen Diagnostics. "We welcome the opportunity to expand our
working relationship with the FASgen Diagnostics team, and are very pleased
that they were willing to select Tetracore as the first outside corporate
investor to participate in their Company," said Dr. William Nelson,
President of Tetracore Inc. "These FAS diagnostic tests represent a new
bio-marker platform test for monitoring cancer and will be highly
complementary to existing tests to the benefit of patients and clinicians,"
said Dr. Frank Kuhajda, Professor of Biochemistry and Pathology at Johns
Hopkins Medical School and a Founder of FASgen Diagnostics, and who is also
credited
'/>"/>
| SOURCE FASgen Diagnostics, LLC Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |